Zenith Drugs Board of Directors

Get the latest insights into the leadership at Zenith Drugs. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Sandeep BhardwajManaging Director
Bhupesh SoniExecutive Director
Ajay Singh DassundiExecutive Director
Ranjana Sureshkumar SehgalNon Executive Independent Director
Deendayal KumawatNon Executive Independent Director
Anil MalikNon Executive Director
Sakshi BhawsarCompany Secretary & Compliance Officer

Zenith Drugs Share price

ZENITHDRUG

40.85

0.65 (-1.57%)
Last updated on 28 Apr, 2026 | 15:31 IST
Today's High

42.00

Today's Low

40.00

52 Week Low

33.30

52 Week High

85.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Zenith Drugs FAQs

The board at Zenith Drugs consists of experienced professionals, including Sandeep Bhardwaj, Bhupesh Soni, and others, overseeing the company’s strategic and corporate governance.

Directors at Zenith Drugs are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Sandeep Bhardwaj is the current chairman at Zenith Drugs.

Executive directors at Zenith Drugs are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Zenith Drugs adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Zenith Drugs, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost